Death receptors and their role in dermatology, with particular focus on tumor necrosis factor‐related apoptosis‐inducing ligand receptors
2003; Wiley; Volume: 42; Issue: 1 Linguagem: Inglês
10.1046/j.1365-4362.2003.01712.x
ISSN1365-4632
AutoresKathleen J. Smith, Hafeez Diwan, Henry G. Skelton,
Tópico(s)NF-κB Signaling Pathways
ResumoInternational Journal of DermatologyVolume 42, Issue 1 p. 3-17 Death receptors and their role in dermatology, with particular focus on tumor necrosis factor-related apoptosis-inducing ligand receptors Kathleen J. Smith MD, Corresponding Author Kathleen J. Smith MD From the Departments of Dermatology and Pathology, University of Alabama at Birmingham, Birmingham, Alabama Kathleen J. Smith, md, Departments of Dermatology and Pathology, University of Alabama at Birmingham, Eye Foundation Building, Suite 414, 1720 University Blvd, Birmingham, AL 35294-0009 E-mail: [email protected]Search for more papers by this authorHafeez Diwan MD, Hafeez Diwan MD From the Departments of Dermatology and Pathology, University of Alabama at Birmingham, Birmingham, AlabamaSearch for more papers by this authorHenry Skelton MD, Henry Skelton MD From the Departments of Dermatology and Pathology, University of Alabama at Birmingham, Birmingham, AlabamaSearch for more papers by this author Kathleen J. Smith MD, Corresponding Author Kathleen J. Smith MD From the Departments of Dermatology and Pathology, University of Alabama at Birmingham, Birmingham, Alabama Kathleen J. Smith, md, Departments of Dermatology and Pathology, University of Alabama at Birmingham, Eye Foundation Building, Suite 414, 1720 University Blvd, Birmingham, AL 35294-0009 E-mail: [email protected]Search for more papers by this authorHafeez Diwan MD, Hafeez Diwan MD From the Departments of Dermatology and Pathology, University of Alabama at Birmingham, Birmingham, AlabamaSearch for more papers by this authorHenry Skelton MD, Henry Skelton MD From the Departments of Dermatology and Pathology, University of Alabama at Birmingham, Birmingham, AlabamaSearch for more papers by this author First published: 04 February 2003 https://doi.org/10.1046/j.1365-4362.2003.01712.xCitations: 11Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001; 15: 1022–1032. 10.1038/sj.leu.2402169 CASPubMedWeb of Science®Google Scholar 2 Schulze-Osthoff K, Ferrari D, Los M, et al. Apoptosis signaling by death receptors. Eur J Biochem 1998; 254: 439–459. 10.1046/j.1432-1327.1998.2540439.x CASPubMedWeb of Science®Google Scholar 3 Boldin MP, Varfolomeev EE, Pancer Z, et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795–7798. 10.1074/jbc.270.14.7795 CASPubMedWeb of Science®Google Scholar 4 Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain containing protein, interacts with death domain of Fas and initiates apoptosis. Cell 1995; 81: 505–512. 10.1016/0092-8674(95)90071-3 CASPubMedWeb of Science®Google Scholar 5 Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD–TRAF2 and TRADD–FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299–308. 10.1016/S0092-8674(00)80984-8 CASPubMedWeb of Science®Google Scholar 6 Hsu H, Huang J, Shu HB, et al. TNF dependent recruitment of the protein kinase RIP to the TNF receptor 1 signaling complex. Immunity 1996; 4: 299–308. 10.1016/S1074-7613(00)80252-6 Web of Science®Google Scholar 7 Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89: 1067–1076. 10.1016/S0092-8674(00)80294-9 CASPubMedWeb of Science®Google Scholar 8 Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479–489. 10.1016/S0092-8674(00)80434-1 CASPubMedWeb of Science®Google Scholar 9 Eskes R, Desagher S, Antonsson B, Martinou J. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 1999; 144: 891–901. Web of Science®Google Scholar 10 Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491–501. 10.1016/S0092-8674(00)81590-1 CASPubMedWeb of Science®Google Scholar 11 Muzio M, Chinnaiyan AM, Kischkel FC, et al. Flice, a novel FADD homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death inducing signaling complex. Cell 1996; 85: 817–827. 10.1016/S0092-8674(00)81266-0 CASPubMedWeb of Science®Google Scholar 12 Stroh C, Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ 1998; 5: 997–1000. 10.1038/sj.cdd.4400451 CASPubMedWeb of Science®Google Scholar 13 Wieder T, Geilen CC, Kolter T, et al. Bcl-2 antagonizes apoptotic cell death induced by two new ceramide analogues. FEBS Lett 1997; 411: 260–264. 10.1016/S0014-5793(97)00717-5 CASPubMedWeb of Science®Google Scholar 14 Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441–446. 10.1038/17135 CASPubMedWeb of Science®Google Scholar 15 Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281–292. 10.1083/jcb.144.2.281 CASPubMedWeb of Science®Google Scholar 16 Pritchard DE, Singh J, Carlisle DL, Patierno SR. Cyclosporin A inhibits chromium(vi)-induced apoptosis and mitochondrial cytochrome c release and restores clonogenic survival in CHO cells. Carcinogenesis 2000; 21: 2027–2033. 10.1093/carcin/21.11.2027 CASPubMedWeb of Science®Google Scholar 17 Okuma E, Saeki K, Shimura M, et al. Induction of apoptosis in human hematopoietic U937 cells by granulocyte macrophage colony-stimulating factor: possible existence of caspase 3-like pathway. Leukemia 2000; 14: 612–619. 10.1038/sj.leu.2401716 CASPubMedWeb of Science®Google Scholar 18 Wang CY, Mayo MW, Korneluk RG, et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and cIAP1 and cIAP2 to suppress caspase-8 activation. Science 1998; 281: 1680–1683. 10.1126/science.281.5383.1680 CASPubMedWeb of Science®Google Scholar 19 Duriez PJ, Wong F, Dorovini-Zis K, et al. A1 functions at the mitochondria to delay endothelial apoptosis in response to tumor necrosis factor. J Biol Chem 2000; 275: 18,099–18,107. 10.1074/jbc.M908925199 PubMedWeb of Science®Google Scholar 20 Brown TD, Goodman P, Fleming T, et al. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother 1991; 10: 376–378. 10.1097/00002371-199110000-00010 PubMedWeb of Science®Google Scholar 21 Kemeny N, Childs B, Larchian W, et al. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 1990; 66: 659–663. 10.1002/1097-0142(19900815)66:4 3.0.CO;2-2 CASPubMedWeb of Science®Google Scholar 22 Lucking-Famira KM, Daniel PT, Moller P, et al. APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. Leukemia 1994; 8: 3166–3173. Google Scholar 23 Ogasawra J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806–809. 10.1038/364806a0 PubMedWeb of Science®Google Scholar 24 Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1 (CD95) mediated apoptosis in human B cells. J Immunol 1994; 152: 5624–5632. CASPubMedWeb of Science®Google Scholar 25 Dhein J, Walczak H, Baumler C, et al. Autocrine T-cell suicide mediated by APO-1/Fas/CD95. Nature 1995; 373: 438–441. 10.1038/373438a0 CASPubMedWeb of Science®Google Scholar 26 Daniel PT, Scholz C, Essmann F, et al. CD95;Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism. Exp Hematol 1999; 4: 21–22. Google Scholar 27 Irisarri M, Plumas J, Bonnefoix T, et al. Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line. Leukemia 2000; 14: 2149–2158. 10.1038/sj.leu.2401954 CASPubMedWeb of Science®Google Scholar 28 Xerri L, Devilard E, Bouabdallah R, et al. Quantitative analysis detects ubiquitous expression of apoptosis regulators in B cell non-Hodgkin's lymphomas. Leukemia 1997; 1: 1868–1877. 10.1038/sj.leu.2400815 Web of Science®Google Scholar 29 Ashkenazi A, Pai RC, Fong S, et al. Safety and anti-tumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162. 10.1172/JCI6926 CASPubMedWeb of Science®Google Scholar 30 Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int J Oncol 1999; 15: 793–802. CASPubMedWeb of Science®Google Scholar 31 Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Nat Med 2000; 6: 564–567. 10.1038/75045 CASPubMedGoogle Scholar 32 Nitsch R, Bechmann I, Deisz RA, et al. Human brain cell death induced by tumour necrosis factor related apoptosis-inducing ligand (TRAIL). Lancet 2000; 95: 827–828. 10.1016/S0140-6736(00)02659-3 Web of Science®Google Scholar 33 Kayagaki N, Yamaguchi N, Nakayama M, et al. Type I interferons regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451. 10.1084/jem.189.9.1451 CASPubMedWeb of Science®Google Scholar 34 Smith CG, Farrah T, Gooswin RG. The TNF receptor superfamily of cellular and viral proteins; activation, costimulation, and death. Cell 1994; 76: 959. 10.1016/0092-8674(94)90372-7 CASPubMedWeb of Science®Google Scholar 35 Chou A-H, Tsai H-F, Lin L-L, et al. Enhanced proliferation and increased IFN-γ production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J Immunol 2001; 167: 1347–1352. 10.4049/jimmunol.167.3.1347 CASPubMedWeb of Science®Google Scholar 36 Harper N, Farrow SN, Kaptein A, et al. Modulation of TRAIL-induced NF-κB activation by inhibition of apical caspases. J Biol Chem 2001; 276: 1–35. Google Scholar 37 Kong Y-Y, Boyle WJ. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000; 21: 495–502. 10.1016/S0167-5699(00)01718-7 CASPubMedWeb of Science®Google Scholar 38 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631–637. 10.1210/jc.86.2.631 CASPubMedWeb of Science®Google Scholar 39 Hofbauer LC, Lacey DL, Dunstan CR, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382–4389. 10.1210/endo.140.10.7034 CASPubMedWeb of Science®Google Scholar 40 Hofbaruer LC, Shui C, Riggs BL, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001; 12 (280): 334–339. 10.1006/bbrc.2000.4130 Web of Science®Google Scholar 41 Jian-Zhong Q, Bacon P, Chaturvedi V, Nickoloff BJ. Role of NF-κB activity in apoptotic response of keratinocytes mediated by interferon-γ, tumor necrosis factor-α, and tumor-necrosis-factor-related apoptosis-inducing ligand. J Invest Dermatol 2001; 117: 898–907. 10.1046/j.0022-202x.2001.01477.x PubMedWeb of Science®Google Scholar 42 Griffith TS, Lynch DH. TRAIL, a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559–563. 10.1016/S0952-7915(98)80224-0 CASPubMedWeb of Science®Google Scholar 43 Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-κB inducers upregulate cFLIP, a cycloheximide sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21: 3964–3973. 10.1128/MCB.21.12.3964-3973.2001 CASPubMedWeb of Science®Google Scholar 44 Wani MR, Fuller K, Kim NS, et al. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 1999; 140: 1927–1935. 10.1210/endo.140.4.6647 CASPubMedWeb of Science®Google Scholar 45 Deveraux QL, Stennicke HR, Salvesen GS, Reed JC. Endogenous inhibitors of caspases. J Clin Immunol 1999; 19: 388–396. 10.1023/A:1020502800208 CASPubMedWeb of Science®Google Scholar 46 Darynkiewicz Z, Carter SP, Old LJ. Effect of recombinant tumor necrosis factor on HL-60 cells; cell-cycle specificity and synergism with actinomycin D. J Cell Physiol 1987; 130: 328–335. 10.1002/jcp.1041300304 PubMedWeb of Science®Google Scholar 47 Isonishi S, Jekunen AP, Hom DK, et al. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. J Clin Invest 1992; 90: 1436–1442. 10.1172/JCI116010 CASPubMedWeb of Science®Google Scholar 48 Micheau O, Solary E, Hammann A, et al. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783–789. 10.1093/jnci/89.11.783 CASPubMedWeb of Science®Google Scholar 49 Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999; 59: 6153–6158. CASPubMedWeb of Science®Google Scholar 50 Wu GS, Kim K, El-Deiry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p-53 tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000; 465: 143–151. 10.1007/0-306-46817-4_13 CASPubMedWeb of Science®Google Scholar 51 Guan B, Yue P, Clayman GL, Sun S-Y. Evidence that the death receptor DR4 is a DNA damage-inducible, p53 regulated gene. J Cell Physiol 2001; 188: 98–105. 10.1002/jcp.1101 CASPubMedWeb of Science®Google Scholar 52 Zhou M, Gu L, Yeager AM, Findley HW. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 1998; 12: 1756–1763. 10.1038/sj.leu.2401198 CASPubMedWeb of Science®Google Scholar 53 Granville DJ, Jiang H, McManus BM, Hunt DW. Fas ligand and TRAIL augment the effect of photodynamic therapy in the induction of apoptosis in JURKAT cells. Int Immunopharmacol 2001; 9–10: 1831–1840. 10.1016/S1567-5769(01)00107-2 Web of Science®Google Scholar 54 Schempp CM, Simon-Haarhaus B, Termeer CC, Simon JC. Hypericin photo-induced apoptosis involves the tumor necrosis factor related apoptosis inducing ligand (TRAIL) and activation of caspase. FEBS Lett 2001; 493: 26–30. 10.1016/S0014-5793(01)02268-2 CASPubMedWeb of Science®Google Scholar 55 Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 714: 19–28. Google Scholar 56 Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1999; 161: 2195–2200. PubMedWeb of Science®Google Scholar 57 Mori S, Murakami-Mori K, Nakamura S, et al. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J Immunol 1999; 162: 5616–5623. CASPubMedWeb of Science®Google Scholar 58 Mitsiades C, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98: 795–804. 10.1182/blood.V98.3.795 CASPubMedWeb of Science®Google Scholar 59 Hardin J, MacLeod S, Grigonieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063–3070. 10.1182/blood.V84.9.3063.3063 CASPubMedWeb of Science®Google Scholar 60 Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000; 275: 27,845–27,850. Google Scholar 61 Rathmell JC, Townsend SE, Xu JC, et al. Expansion or elimination of B cell antigen receptor. Cell 1996; 87: 319–329. 10.1016/S0092-8674(00)81349-5 CASPubMedWeb of Science®Google Scholar 62 Rothstein TL, Wang JKM, Parks DJ, et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374: 163–165. 10.1038/374163a0 CASPubMedWeb of Science®Google Scholar 63 Marks R. An overview of skin cancers. Incidence and causation. Cancer 1995; 75: 607–612. 10.1002/1097-0142(19950115)75:2+ 3.0.CO;2-8 PubMedWeb of Science®Google Scholar 64 Solary E, Droin N, Bettaib A, et al. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 2000; 14: 1833–1849. 10.1038/sj.leu.2401902 CASPubMedWeb of Science®Google Scholar 65 Hill LL, Ouhtit A, Loughlin SM, et al. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 1999; 285: 898–900. 10.1126/science.285.5429.898 CASPubMedWeb of Science®Google Scholar 66 Gottlieb TM, Oren M. p53 and apoptosis. Semin Cancer Biol 1998; 8: 359–368. 10.1006/scbi.1998.0098 CASPubMedWeb of Science®Google Scholar 67 Bachmann F, Buechner SA, Wernli M, et al. Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation. J Invest Dermatol 2001; 117: 59–66. 10.1046/j.0022-202x.2001.01380.x CASPubMedWeb of Science®Google Scholar 68 Leverkus M, Neurmann M, Megling T, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553–559. CASPubMedWeb of Science®Google Scholar 69 Sheikh MS, Antinore MJ, Huang Y, Torance AJ. Ultraviolet-irradiation-induced apoptosis is mediated via ligand independent activation of tumor necrosis factor receptor 1. Oncogene 1998; 17: 2555–2563. 10.1038/sj.onc.1202292 CASPubMedWeb of Science®Google Scholar 70 Devary Y, Rosette C, Didonato JA, Karin M. NF-kappaB activation by ultraviolet light not dependent on a nuclear signal. Science 1993; 261: 1442–1445. 10.1126/science.8367725 CASPubMedWeb of Science®Google Scholar 71 Kulms D, Poppelmann B, Yarosh D, et al. Nuclear and cell membrane effects contribute independently to the induction of apoptosis in human cells exposed to UVB radiation. Proc Natl Acad Sci USA 1999; 96: 7974–7979. 10.1073/pnas.96.14.7974 CASPubMedWeb of Science®Google Scholar 72 Tron VA, Trotter MJ, Tang L, et al. p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am J Pathol 1998; 153: 579–585. 10.1016/S0002-9440(10)65600-3 CASPubMedWeb of Science®Google Scholar 73 Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699–703. 10.1038/25387 CASPubMedWeb of Science®Google Scholar 74 Maeda T, Hao C, Tron VA. Ultraviolet light (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes. J Cutan Med Surg 2001; online 18 July: 1–7. Google Scholar 75 Gutierrez-Steil C, Wrone-Smith T, Sun X, et al. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet b irradiated psoriatic plaques express Fas ligand (CD95L). J Clin Invest 1998; 101: 33–39. 10.1172/JCI1165 CASPubMedWeb of Science®Google Scholar 76 Zhang XD, Franco AV, Nguyen T, et al. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000; 164: 3961–3970. 10.4049/jimmunol.164.8.3961 CASPubMedWeb of Science®Google Scholar 77 Filipowicz W, Adegboyega P, Sanchez RL, Gatalica Z. Expression of CD95 (Fas) in sunexposed human skin and cutaneous carcinomas. Cancer 2002; 94: 814–819. 10.1002/cncr.10277 CASPubMedWeb of Science®Google Scholar 78 Zeimer AG, Riha K, Berger J, et al. New insights into p53 regulation and gene therapy for cancer. Biochem Pharmacol 2000; 60: 1153–1163. 10.1016/S0006-2952(00)00442-1 PubMedWeb of Science®Google Scholar 79 Franco AV, Zhang XD, Van Berkel E, et al. The role of NF-kappaB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001; 166: 5337–5345. 10.4049/jimmunol.166.9.5337 CASPubMedWeb of Science®Google Scholar 80 Bullani RR, Huard B, Viard-Leveogle I, et al. Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 2001; 17: 360–364. 10.1046/j.0022-202x.2001.01418.x Web of Science®Google Scholar 81 Griffith TS, Wiley SR, Kubin MZ, et al. Monocyte-mediated tumoricidal activity via tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189: 1434–1453. 10.1084/jem.189.8.1343 Web of Science®Google Scholar 82 Sedger LM, Shows DM, Blanton RA, et al. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163: 920–926. CASPubMedWeb of Science®Google Scholar 83 Nguyen T, Wayne T, Zhang X-D, et al. Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Trends Exp Clin Med 2000; 10: 243–252. CASGoogle Scholar 84 Fadeel B, Orrenius S, Zhivotovsky B. The most unkindest cut of all: on the multiple roles of mammalian caspases. Leukemia 2000; 14: 1514–1525. 10.1038/sj.leu.2401871 CASPubMedWeb of Science®Google Scholar 85 Buechner SA, Wernli M, Harr T, et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)–CD95 ligand-induced suicide. J Clin Invest 1997; 1: 2691–2696. 10.1172/JCI119814 Web of Science®Google Scholar 86 Reilly CM, Gilkesson GS. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunol Res 2002; 25: 143–153. 10.1385/IR:25:2:143 CASPubMedWeb of Science®Google Scholar 87 Mullauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 2001; 488: 211–231. 10.1016/S1383-5742(01)00057-6 CASPubMedWeb of Science®Google Scholar 88 Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001; 144: 958–966. 10.1046/j.1365-2133.2001.04182.x CASPubMedWeb of Science®Google Scholar 89 Silvestris F, Williams RC, Calvani N, et al. Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease. Clin Exp Med 2002; 2: 13–27. 10.1007/s102380200002 CASPubMedWeb of Science®Google Scholar 90 Miret C, Font J, Molina R, et al. Relationship of oncogenes (sFAS, Bcl-2) and cytokines (IL-10 and alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res 2001; 21: 3053–3059. CASPubMedWeb of Science®Google Scholar 91 Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540–1543. 10.1126/science.1064890 CASPubMedWeb of Science®Google Scholar 92 Aringer M, Feier LE, Steiner G, et al. Increased bioactive TNF in human systemic Lupus Erythematosus: associations with cell death. Lupus 2002; 11: 102–108. Google Scholar 93 Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001; 40: 275–284. 10.2169/internalmedicine.40.275 CASPubMedWeb of Science®Google Scholar 94 Via CS, Shustov A, Rus V, et al. In vivo neutralization of TNF-α promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001; 167: 6821–6826. 10.4049/jimmunol.167.12.6821 CASPubMedWeb of Science®Google Scholar 95 Viard I, Welrih P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockage of CD95 with intravenous immunoglobulin. Science 1998; 292: 490–493. 10.1126/science.282.5388.490 Web of Science®Google Scholar 96 Stella M, Cassano P, Bollero D, et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins; our experience. Dermatology 2001; 203: 45–49. 10.1159/000051702 CASPubMedWeb of Science®Google Scholar 97 Duvic M, Helekar B, Schulz C, et al. Expression of retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res 2000; 6: 3249–3259. CASPubMedWeb of Science®Google Scholar 98 Atucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 662–664. 10.1038/89031 PubMedWeb of Science®Google Scholar 99 Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor related apoptosis inducing ligand (TRAIL) induced apoptosis by the synthetic retinoid 6-(3-adamantyl)-4-hydroxyphenyl)-2-naphthalene carboxylic acid through up-regulation of TRAIL receptors in human lung cancer. Cancer Res 2000; 60: 7149–7155. CASPubMedWeb of Science®Google Scholar 100 Sun SY, Yue P, Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000; 19: 4513–4522. 10.1038/sj.onc.1203810 CASPubMedWeb of Science®Google Scholar 101 Keane MM, Ettenberg SA, Nau MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cancer lines. J Cancer Res 1999; 59: 734–741. CASPubMedWeb of Science®Google Scholar 102 Percario ZA, Giandomenico V, Fiorucci G, et al. Retinoic acid is able to induce interferon regulatory factor 1 in squamous carcinoma cells via a STAT-1 independent signalling pathway. Cell Growth Diff 1999; 10: 263–270. CASPubMedWeb of Science®Google Scholar 103 Um S-J, Kim E-J, Hwang E-S, et al. Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. Int J Cancer 2000; 85: 416–423. 10.1002/(SICI)1097-0215(20000201)85:3 3.0.CO;2-3 CASPubMedWeb of Science®Google Scholar 104 McGuire TF, Trump DL, Johnson CS. Vitamin D3 induced apoptosis of murine squamous cell carcinoma cells. J Biol Chem 2001; 276: 26,365–26,373. 10.1074/jbc.M010101200 Web of Science®Google Scholar 105 Sporn MB, Suuh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001; 7: 395–400. 10.1016/S1471-4914(01)02100-1 CASPubMedWeb of Science®Google Scholar 106 Goke R, Goke A, Goke B, Chen Y. Regulation of TRAIL-induced apoptosis by transcription factors. Cell Immunol 2000; 201: 77–82. 10.1006/cimm.2000.1650 CASPubMedWeb of Science®Google Scholar 107 Yoshida M, Furumai R, Nishiyama M, et al. Histone deacetylase as a new target for cancer chemotherapy. Can Chemother Pharmacol 2001; 48: 1s20–1s26. Google Scholar 108 Sheldon LA, Becker M, Smith CL. Steroid hormone receptor-mediated histone deacetylation and transcription at the mouse mammary tumor virus promoter. J Biol Chem 2001; 276: 32,423–32,426. 10.1074/jbc.C100315200 Web of Science®Google Scholar 109 Hung WC, Chuang LY. Sodium butyrate enhances STAT-1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha. Br J Cancer 1999; 80: 705–710. 10.1038/sj.bjc.6690413 CASPubMedWeb of Science®Google Scholar 110 Bernhard D, Skvortsow S, Tinhofer I, et al. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ 2001; 8: 1014–1021. 10.1038/sj.cdd.4400914 CASPubMedWeb of Science®Google Scholar 111 Chen L-F, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001; 293: 1653–1657. 10.1126/science.1062374 CASPubMedWeb of Science®Google Scholar 112 Harda H, Taniguchi T, Tanaka N. The role of interferon regulatory factors in the interferon system and cell growth. Biochimie 1998; 80: 641–650. 10.1016/S0300-9084(99)80017-0 PubMedWeb of Science®Google Scholar 113 Stancato LF, David M, Carter-Su C, et al. Preassociation of STAT1 with STAT2 and STAT3 in separate signalling complexes prior to cytokine stimulation. J Biol Chem 1996; 271: 4134–4137. 10.1074/jbc.271.8.4134 CASPubMedWeb of Science®Google Scholar 114 Blanco JCG, Contursi C, Salkowski CA, et al. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon γ dependent cyclooxygenase 2 expression. J Exp Med 2000; 191: 2131–2144. 10.1084/jem.191.12.2131 CASPubMedWeb of Science®Google Scholar 115 Demplke W, Rie C, Grothey A, Schmoll H-J. Cyclooxygenase-2; a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001; 127: 41–47. Google Scholar 116 Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 2000; 17: 109–157. 10.1515/DMDI.2000.17.1-4.109 CASPubMedGoogle Scholar 117 Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000; 86: 667–671. 10.1002/(SICI)1097-0215(20000601)86:5 3.0.CO;2-Y CASPubMedWeb of Science®Google Scholar 118 Steele VE, Holmes CA, Hawk ET, et al. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Invest Drugs 2000; 9: 121–138. 10.1517/13543784.9.9.2121 Web of Science®Google Scholar 119 Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001; 15: 2007–2009. 10.1096/fj.00-0866fje CASPubMedWeb of Science®Google Scholar 120 Bromberg JF, Wrzeszczynska MH, Devgan G, et al. STAT3 as an oncogene. Cell 1999; 98: 295–303. 10.1016/S0092-8674(00)81959-5 CASPubMedWeb of Science®Google Scholar 121 Webb BL, Jimenez E, Martin GS. V-Src generates a p53-independent apoptotic signal. Mol Cell Biol 2000; 20: 9271–9280. 10.1128/MCB.20.24.9271-9280.2000 CASPubMedWeb of Science®Google Scholar 122 Horn MA, Gordon KB. Chemoprevention of skin cancer. Cancer Treat Res 2001; 106: 255–282. 10.1007/978-1-4615-1657-6_11 CASPubMedGoogle Scholar 123 Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001; 58: 244–258. 10.1007/PL00000852 CASPubMedWeb of Science®Google Scholar 124 Weisburger EK. Chemoprevention of cancer: a brief review. In Vivo 2000; 14: 699–701. CASPubMedWeb of Science®Google Scholar 125 Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(Difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000; 9: 1281–1290. CASPubMedWeb of Science®Google Scholar 126 Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leuk Biol 2002; 71: 565–581. 10.1189/jlb.71.4.565 CASPubMedWeb of Science®Google Scholar 127 Arany I, Tyring SK, Brysk MM, et al. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (imiquimod) in genital warts. Antimicrob Agents Chemother 2000; 44: 1869–1873. 10.1128/AAC.44.7.1869-1873.2000 CASPubMedWeb of Science®Google Scholar 128 Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway 2002; 3: 196–200. Google Scholar 129 Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863–869. 10.1084/jem.194.6.863 CASPubMedWeb of Science®Google Scholar 130 Chuang T-H, Ulevitch RJ. Cloning and characterization of a subfamily of human Toll-like receptors: hTLR7, hTLR8, and hTLR9. Eur Cyto Netw 2000; 11: 372–378. CASPubMedWeb of Science®Google Scholar 131 Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61: 3330–3338. CASPubMedWeb of Science®Google Scholar Citing Literature Volume42, Issue1January 2003Pages 3-17 ReferencesRelatedInformation
Referência(s)